BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q1 2025 Earnings Call Transcript
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q1 2025 Earnings Call Transcript May 14, 2025BioRestorative Therapies, Inc. misses on earnings expectations.
Biorestorative Therapies Inc. (BRTX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.25 | 6,600 | $8,250.00 | 155,759 | 2024-04-09 | Filing | |
| $1.17 | 1,232 | $1,441.44 | 149,159 | 2024-04-08 | Filing | |
| $1.13 | 476 | $537.88 | 147,927 | 2024-04-08 | Filing | |
| $1.32 | 86,041 | $113,574.12 | 477,972 | 2024-02-09 | Filing | |
| $1.25 | 73,959 | $92,448.75 | 391,931 | 2024-02-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.58 | 1,112 | $1,756.96 | 445,933 | 2024-10-28 | Filing | |
| $1.88 | 250 | $469.25 | 327,045 | 2023-12-01 | Filing | |
| $1.89 | 278 | $525.42 | 327,295 | 2023-11-27 | Filing | |
| $3.39 | 3,958 | $13,409.70 | 158,156 | 2022-08-26 | Filing | |
| $3.44 | 2,000 | $6,875.60 | 257,303 | 2022-05-26 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 59,997 | $106,793 | 0% | |
| 2. | 40,000 | $71,200 | 0.01% | |
| 3. | 38,000 | $67,640 | 0% | |
| 4. | 29,730 | $52,919 | 0% | |
| 5. | 20,459 | $36,417 | 0% |
News See All
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and welcome to the BioRestorative Therapies 2024 Results Conference Call.
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q3 2024 Earnings Call Transcript
Operator: Greetings. Welcome to the BioRestorative Third Quarter 2024 Results and New Additional Preliminary BRTX-100 Phase 2 Study Data Review Conference Call.
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q2 2024 Earnings Call Transcript
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q2 2024 Earnings Call Transcript August 13, 2024BioRestorative Therapies, Inc. beats earnings expectations.
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and welcome to the BioRestorative Therapies Q1 Business Update Conference Call.
10 Micro-Cap Healthcare Stocks Insiders Are Buying
In this article, we will take a detailed look at the 10 Micro-Cap Healthcare Stocks Insiders Are Buying. For a quick overview of such stocks, read our article 5 Micro-Cap Healthcare Stocks Insiders...
5 Buy-Rated Stocks with Latest Insider Purchases
Robert James Wills, a director at Oncternal Therapeutics Inc (NASDAQ:ONCT), bought 3,086 shares of Oncternal Therapeutics Inc (NASDAQ:ONCT) at $8.96 per share.
11 Most Volatile Stocks Under $5 For Day Trading
In this piece, we will take a look at the 11 most volatile stocks under $5 for day trading.
Hedge Fund and Insider Trading News: Paul Marshall, Crispin Odey, Point72 Asset Management, Asgard Fixed Income Fund, Brookfield Hedge Solutions Advisors, B Riley Financial Inc (RILY), Verrica Pharmaceuticals Inc. (VRCA), and More
GB News owner Sir Paul Marshall’s hedge fund has made a multi-million pound gain on its bet against NatWest shares following the exit of Dame Alison Rose.